3-氟-5-甲氧羰基苯基硼酸 | 871329-62-3

• 物质功能分类: 化学试剂 - 有机试剂 - 硼酸
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-氟-5-甲氧羰基苯基硼酸
• 中文别名: 3-氟-5-甲氧羰基苯硼酸
• 英文名称: (3-fluoro-5-(methoxycarbonyl)phenyl)boronic acid
• 英文别名: 3-Fluoro-5-methoxycarbonylphenylboronic acid；(3-fluoro-5-methoxycarbonylphenyl)boronic acid
• CAS: 871329-62-3
• 化学式: C₈H₈BFO₄
• mdl: MFCD07363749
• 分子量: 197.959
• InChiKey: VKHJVASTGLPBBL-UHFFFAOYSA-N

物化性质

• 熔点：
  138-142
• 沸点：
  372.5±52.0 °C(Predicted)
• 密度：
  1.33±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.93
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  66.8
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2931900090
• 危险性防范说明：
  P261,P280,P305+P351+P338,P304+P340,P405,P501
• 危险性描述：
  H302
• 储存条件：
  2-8℃

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
3-Fluoro-5-methoxycarbonylphenylboronic acid
Product Name:
Synonyms: Methyl 3-borono-5-fluorobenzoate

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
3-Fluoro-5-methoxycarbonylphenylboronic acid
Ingredient name:
CAS number: 871329-62-3

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C8H8BFO4
Molecular weight: 198.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-氟-5-甲氧羰基苯基硼酸 在 4-二甲氨基吡啶 、 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 palladium bis[bis(diphenylphosphino)ferrocene] dichloride 、 lithium hydroxide monohydrate 、 一水合肼 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三氯氧磷 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 乙醇 、 二氯甲烷 、 水 为溶剂， 反应 15.5h， 生成 (R)-N-(1-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)ethyl)-4-(5-(3-fluoro-5-(pyridin-2-yl)phenyl)-1,3,4-oxadiazol-2-yl)benzamide
  参考文献：
  名称：

  基于甾醇14α-脱甲基酶结构的VNI（（R）-N-（1-（2,4-二氯苯基）-2-（1 H-咪唑-1-基）乙基）-4-（5-苯基- 1,3,4-恶二唑-2-基）苯甲酰胺））靶向真菌感染的衍生物：合成，生物学评估和晶体学分析

  摘要：

  由于免疫受损患者数量的增加，侵袭性真菌感染的发生率正在增加，但是治疗效率仍然低得令人无法接受。临床上最有效的系统性抗真菌药（唑类）是两种支架的衍生物：酮康唑和氟康唑。作为最安全的抗真菌药物，它们仍然存在缺点，主要是由于药代动力学和耐药性。在这里，我们报告了目标真菌酶，甾醇14α-脱甲基酶（CYP51），通过对VNI [（R）-N-（1-（2,4， -二氯苯基）-2-（1 H-咪达唑-1-基）乙基）-4-（5-苯基-1,3,4-恶二唑-2-基）苯甲酰胺）]，这是一种原生动物CYP51的抑制剂，可治愈南美锥虫病。面向真菌的VNI衍生物的合成，其抑制两种主要真菌病原体（烟曲霉和白色念珠菌）CYP51s的能力，微粒体稳定性，对真菌细胞的作用以及最复杂的烟曲霉CYP51的结构表征描述了有效的化合物，提供了新的抗真菌药物支架并概述了进一步优化的方向。

  DOI：

  10.1021/acs.jmedchem.8b00641
• 作为产物：
  描述：

  甲醇 、 3-羧基-5-氟苯基硼酸 在 硫酸 作用下， 以94%的产率得到3-氟-5-甲氧羰基苯基硼酸
  参考文献：
  名称：

  [EN] IMIDAZOTHIADIAZOLE AND IMIDAZOPYRIDAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION
  [FR] DÉRIVÉS D'IMIDAZOTHIADIAZOLE ET D'IMIDAZOPYRIDAZINE UTILES COMME INHIBITEURS DES RÉCEPTEURS 4 ACTIVÉS PAR LES PROTÉASES (PAR4) POUR TRAITER L'AGRÉGATION PLAQUETTAIRE

  摘要：

  本发明提供了公式（I）的咪唑噻二唑化合物；其中W、Y、R0、R2、R4、Ra、Rb、X1、X2、X3和X4如本文所定义，或其立体异构体、互变异构体、药用可接受的盐、前药酯或溶剂化合物形式，其中所有变量如本文所定义。这些化合物是血小板聚集抑制剂，因此可用作治疗或预防血栓栓塞性疾病的药物。

  公开号：

  WO2013163241A1

文献信息

• [EN] GPR52 MODULATOR COMPOUNDS<br/>[FR] COMPOSÉS MODULATEURS DE GPR52
  申请人：HEPTARES THERAPEUTICS LTD

  公开号：WO2021090030A1

  公开（公告）日：2021-05-14

  The disclosures herein relate to novel compounds of Formula (1): (1) and salts thereof, wherein R1, Q, X, Y and Z are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with GPR52 receptors.

  本公开涉及式(1)的新颖化合物： (1)及其盐，其中R1、Q、X、Y和Z的定义如本文中所述，以及它们用于治疗、预防、改善、控制或降低与GPR52受体相关的疾病的风险。
• MODULATORS OF ALPHA-1 ANTITRYPSIN
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20200361939A1

  公开（公告）日：2020-11-19

  The disclosure provides compounds useful for treating alpha-1 antitrypsin deficiency (AATD), according to formula (I): tautomers thereof, pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable salts of the tautomers, deuterated derivatives of the compounds, deuterated derivatives of the tautomers, and deuterated derivatives of the salts, solid forms of those compounds and processes for making those compounds.

  该披露提供了用于治疗α-1抗胰蛋白酶缺乏症（AATD）的化合物，其化学式为（I）：它们的互变异构体，这些化合物的药用盐，这些互变异构体的药用盐，这些化合物的氘代衍生物，这些互变异构体的氘代衍生物，以及这些盐的氘代衍生物，这些化合物的固态形式以及制备这些化合物的方法。
• Ruthenium complexes as sensitizers with phenyl-based bipyridine anchoring ligands for efficient dye-sensitized solar cells
  作者：Yin Huang、Wang-Chao Chen、Xian-Xi Zhang、Rahim Ghadari、Xia-Qin Fang、Ting Yu、Fan-Tai Kong

  DOI：10.1039/c8tc03288b

  日期：——

  Two ruthenium complex dye sensitizers, Ru(NCS)2 LL′, in which L refers to 4,4′-dinonyl-2,2′-bipyridine and L′ stands for 4,4′-di(m-X-benzoic acid)-2,2′-bipyridine (X = H (RC-73), F (RC-76)), were designed and synthesized to investigate the influence of introducing phenyl-based bipyridine anchoring ligands and the performance of dye-sensitized solar cells based on them. With the modification of conventional

  两种钌络合物染料敏化剂Ru（NCS）2 LL'，其中L代表4,4'-二壬基-2,2'-联吡啶，L'代表4,4'-二（m -X-苯甲酸） ）-2,2'-联吡啶（X = H（RC-73），F（RC-76））被设计和合成，以研究引入苯基基联吡啶锚定配体的影响以及染料敏化太阳能电池的性能基于它们的单元格。通过用基于苯基的联吡啶单元对常规的4,4'-二羧酸-2,2'-联吡啶基锚定配体进行修饰，两种RC染料均显示出优异的光物理和电化学性能，从而获得出色的器件性能。显着地，随着X的吸电子能力的增强，RC-76在吸收强度，氧化还原电势，电子传输和染料再生方面具有更令人满意的性能，这可以通过紫外可见吸收光谱法，循环伏安法测量，密度泛函理论计算和瞬态吸收光谱法得到证实。基于RC-76的设备实现了17.52 mA cm -2的短路电流密度和9.23％的功率转换效率。动力学研究和电阻抗光谱学解释了与标准Z907染
• IMIDAZOTHIADIAZOLE AND IMIDAZOPYRIDAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20150119390A1

  公开（公告）日：2015-04-30

  The present invention provides imidazothiadiazole compounds of Formula (I); Wherein W, Y, R 0 , R 2 , R 4 , R a , R b , X 1 , X 2 , X 3 and X 4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.

  本发明提供了式(I)的咪唑噻二唑化合物；其中W、Y、R0、R2、R4、Ra、Rb、X1、X2、X3和X4如本文所定义，或其立体异构体、互变异构体、药学上可接受的盐、前药酯或其溶剂化合物形式，其中所有变量均如本文所定义。这些化合物是血小板聚集抑制剂，因此可用作治疗或预防血栓栓塞性疾病的药物。
• COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1
  申请人：Furet Pascal

  公开号：US20150183801A1

  公开（公告）日：2015-07-02

  The present invention relates to compounds of formula (I): in which Y, Y, R, R 2, R 3 and R 4 are defined in the Summary of the Invention; capable of inhibiting the activity of BCR-ABL1 and mutants thereof. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds in the treatment of cancers.

  本发明涉及式(I)的化合物：其中Y，Y，R，R2，R3和R4在发明摘要中定义; 能够抑制BCR-ABL1及其突变体的活性。本发明还提供了一种制备本发明化合物的方法，包括这些化合物的制药制剂以及使用这些化合物治疗癌症的方法。